Loading people...
Gur Roshwalb is a Partner and Managing Director at aMoon Fund, based in Ra'anana, Israel. In this current role, he oversees global healthcare investments for the venture firm, which manages over $1.1 billion in total assets, focusing primarily on late-stage opportunities through the aMoon II fund. Before transitioning to venture capital, he served as the Chief Executive Officer of the NASDAQ-listed biotechnology firm Akari Therapeutics, stepping down in May 2018 after leading its formation via a corporate merger. His earlier financial career includes prominent positions as a Vice President at Venrock and a senior equity analyst at Piper Jaffray. Holding a medical degree from the Albert Einstein College of Medicine alongside a Master of Business Administration, Roshwalb leverages his extensive clinical and operational background to identify and scale emerging biopharma and healthtech companies.
Gur Roshwalb, MD, serves as a highly respected Partner at aMoon Fund, a prominent global venture capital firm dedicated to investing in disruptive health-tech and life sciences companies. In his pivotal role at aMoon Fund, Dr. Roshwalb is instrumental in identifying, evaluating, and nurturing innovative startups that are poised to reshape the future of healthcare. His deep understanding of both clinical medicine and business strategy makes him a valuable asset to the fund and its portfolio companies.
Dr. Roshwalb's investment focus areas at aMoon Fund span a broad spectrum of cutting-edge healthcare technologies. He is particularly interested in digital health solutions that enhance patient engagement and outcomes, advanced medical devices that improve diagnostics and treatment, and groundbreaking biotechnology and pharmaceutical ventures addressing unmet medical needs. His work supports companies developing solutions in areas like AI-powered diagnostics, remote patient monitoring, personalized medicine, and novel therapeutic platforms. He seeks out innovations that offer significant clinical impact and market potential, driving aMoon's mission to invest in the next generation of healthcare leaders.
Before joining aMoon Fund, Dr. Roshwalb built an impressive career marked by leadership and entrepreneurial success. He previously served as CEO of several public and private biotech companies, demonstrating his capability to guide companies from early-stage development through significant growth and strategic exits. Notably, he co-founded and served as CEO of Neurovance, a company later acquired by Neos Therapeutics, showcasing his acumen in building and scaling successful ventures. Earlier in his career, Dr. Roshwalb held a key leadership position as Vice President, Head of CNS at Forest Laboratories (now part of Allergan/AbbVie), where he gained extensive experience in pharmaceutical development and commercialization.
Academically, Dr. Roshwalb holds a medical degree from the prestigious Albert Einstein College of Medicine, followed by a residency in Psychiatry at Columbia University. Further complementing his medical background, he earned an MBA from Columbia Business School, equipping him with a unique blend of clinical insight and strategic business acumen. This diverse educational and professional background allows him to approach healthcare investments with a comprehensive perspective, understanding both the scientific rigor required for medical innovation and the commercial viability essential for market success. Through his work at aMoon Fund, Gur Roshwalb continues to be a driving force in advancing global health through strategic venture capital investments.
Gur Roshwalb, MD, is a Partner at aMoon Fund, a global health-tech and life sciences venture capital firm. He is a physician and experienced biotech executive who leverages his medical and business expertise to invest in transformative healthcare technologies.
Gur Roshwalb invests in disruptive health-tech and life sciences companies through aMoon Fund. His focus areas include digital health, advanced medical devices, biotechnology, and pharmaceutical ventures that aim to revolutionize patient care and healthcare delivery.
Gur Roshwalb works as a Partner at aMoon Fund, a leading global venture capital firm specializing in health-tech and life sciences investments.
